The Interplay among Glucocorticoid Therapy, Platelet-Activating Factor and Endocannabinoid Release Influences the Inflammatory Response to COVID-19

COVID-19 is associated with a dysregulated immune response. Currently, several medicines are licensed for the treatment of this disease. Due to their significant role in inhibiting pro-inflammatory cytokines and lipid mediators, glucocorticoids (GCs) have attracted a great deal of attention. Similarly, the endocannabinoid (eCB) system regulates various physiological processes including the immunological response. Additionally, during inflammatory and thrombotic processes, phospholipids from cell membranes are cleaved to produce platelet-activating factor (PAF), another lipid mediator. Nonetheless, the effect of GCs on this lipid pathway during COVID-19 therapy is still unknown. This is a cross-sectional study involving COVID-19 patients (n = 200) and healthy controls (n = 35). Target tandem mass spectrometry of plasma lipid mediators demonstrated that COVID-19 severity affected eCBs and PAF synthesis. This increased synthesis of eCB was adversely linked with systemic inflammatory markers IL-6 and sTREM-1 levels and neutrophil counts. The use of GCs altered these lipid pathways by reducing PAF and increasing 2-AG production. Corroborating this, transcriptome analysis of GC-treated patients blood leukocytes showed differential modulation of monoacylglycerol lipase and phospholipase A2 gene expression. Altogether, these findings offer a breakthrough in our understanding of COVID-19 pathophysiology, indicating that GCs may promote additional protective pharmacological effects by influencing the eCB and PAF pathways involved in the disease course.

[1]  S. Konno,et al.  Combination therapy with remdesivir and immunomodulators improves respiratory status in COVID‐19: A retrospective study , 2022, Journal of medical virology.

[2]  M. Cardinale,et al.  A Retrospective Study of Dexamethasone, Remdesivir, and Baricitinib in Severe COVID-19 , 2022, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

[3]  Y. L. Tan,et al.  COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt? , 2022, Pharmacological Research.

[4]  D. Antonacci,et al.  The function of specialized pro-resolving endogenous lipid mediators, vitamins, and other micronutrients in the control of the inflammatory processes: Possible role in patients with SARS-CoV-2 related infection , 2022, Prostaglandins & Other Lipid Mediators.

[5]  J. Cleland,et al.  Systemic administration of glucocorticoids, cardiovascular complications and mortality in patients hospitalised with COVID-19, SARS, MERS or influenza: A systematic review and meta-analysis of randomised trials , 2021, Pharmacological Research.

[6]  C. Fuzo,et al.  sTREM-1 Predicts Disease Severity and Mortality in COVID-19 Patients: Involvement of Peripheral Blood Leukocytes and MMP-8 Activity , 2021, Viruses.

[7]  M. Nagarkatti,et al.  Endocannabinoid Anandamide Attenuates Acute Respiratory Distress Syndrome through Modulation of Microbiome in the Gut-Lung Axis , 2021, Cells.

[8]  A. Giacometti,et al.  Possible harm from glucocorticoid drugs misuse in the early phase of SARS-CoV-2 infection: a narrative review of the evidence , 2021, Internal and Emergency Medicine.

[9]  P. Meybohm,et al.  Antibiotics for the treatment of COVID-19. , 2021, The Cochrane database of systematic reviews.

[10]  M. Giera,et al.  The Role of Innate Immunity and Bioactive Lipid Mediators in COVID-19 and Influenza , 2021, Frontiers in Physiology.

[11]  M. Nagarkatti,et al.  The Endocannabinoid Anandamide Attenuates Acute Respiratory Distress Syndrome by Downregulating miRNA that Target Inflammatory Pathways , 2021, Frontiers in Pharmacology.

[12]  M. Akbari,et al.  The effect of omega-3 fatty acid supplementation on clinical and biochemical parameters of critically ill patients with COVID-19: a randomized clinical trial , 2021, Journal of Translational Medicine.

[13]  M. R. Iyer,et al.  Dual inhibition of CB1 receptors and iNOS, as a potential novel approach to the pharmacological management of acute and long COVID‐19 , 2021, British journal of pharmacology.

[14]  O. Lucaciu,et al.  In quest of a new therapeutic approach in COVID-19: the endocannabinoid system , 2021, Drug metabolism reviews.

[15]  M. Falasca,et al.  Dissecting lipid metabolism alterations in SARS-CoV-2 , 2021, Progress in Lipid Research.

[16]  J. Mackenzie,et al.  Lipid droplets and lipid mediators in viral infection and immunity , 2021, FEMS microbiology reviews.

[17]  G. FitzGerald,et al.  Bioactive lipids in antiviral immunity , 2021, Science.

[18]  É. Vivier,et al.  Complement cascade in severe forms of COVID‐19: Recent advances in therapy , 2020, European journal of immunology.

[19]  R. Wong.  Inflammation in COVID-19: from pathogenesis to treatment. , 2021, International journal of clinical and experimental pathology.

[20]  W. Lim,et al.  Dexamethasone in Hospitalized Patients with Covid-19 , 2021 .

[21]  Sanjay Kumar,et al.  CB2 receptor‐selective agonists as candidates for targeting infection, inflammation, and immunity in SARS‐CoV‐2 infections , 2020, Drug development research.

[22]  T. Theoharides,et al.  COVID‐19, microthromboses, inflammation, and platelet activating factor , 2020, BioFactors.

[23]  T. Theoharides,et al.  Coronavirus 2019, Microthromboses, and Platelet Activating Factor , 2020, Clinical Therapeutics.

[24]  A. Kurniawan,et al.  Dyslipidemia is associated with severe coronavirus disease 2019 (COVID-19) infection , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[25]  R. J. Tofano,et al.  Metabolic syndrome and COVID-19 , 2020, AIMS Bioengineering.

[26]  Sharon J Peacock,et al.  Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. , 2020, JAMA.

[27]  S. Luo,et al.  Targeting inflammation and cytokine storm in COVID-19 , 2020, Pharmacological Research.

[28]  P. Datta,et al.  SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy , 2020, Theranostics.

[29]  G. Keser,et al.  Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment , 2020, Clinical Rheumatology.

[30]  Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7) , 2020, Chinese Medical Journal.

[31]  Zhi-Chun Gu,et al.  Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis , 2020, Pharmacological Research.

[32]  Yingzi Huang,et al.  Clinical characteristics and outcomes of critically ill patients with novel coronavirus infectious disease (COVID-19) in China: a retrospective multicenter study , 2020, Intensive Care Medicine.

[33]  M. Ashraf,et al.  Biochemistry, Platelet Activating Factor , 2020 .

[34]  I. Vlodavsky,et al.  The Potential of Low Molecular Weight Heparin to Mitigate Cytokine Storm in Severe COVID‐19 Patients: A Retrospective Cohort Study , 2020, Clinical and translational science.

[35]  Y. Xiong,et al.  Clinical features and treatment of COVID‐19 patients in northeast Chongqing , 2020, Journal of medical virology.

[36]  Xin Zhou,et al.  Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China , 2020, The Journal of Emergency Medicine.

[37]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[38]  Barbara L F Kaplan,et al.  Immune Responses Regulated by Cannabidiol , 2020, Cannabis and cannabinoid research.

[39]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[40]  Qin Ning,et al.  Clinical and immunological features of severe and moderate coronavirus disease 2019 , 2020 .

[41]  I. Zabetakis,et al.  Forty Years Since the Structural Elucidation of Platelet-Activating Factor (PAF): Historical, Current, and Future Research Perspectives , 2019, Molecules.

[42]  J. Zhan,et al.  Cannabinoid receptor 2: a potential novel therapeutic target for sepsis? , 2019, Acta clinica Belgica.

[43]  G. Cabral.  Emerging Role of the CB2 Cannabinoid Receptor in Immune Regulation and Therapeutic Prospects , 2019 .

[44]  C. Libert,et al.  Therapeutic Mechanisms of Glucocorticoids , 2018, Trends in Endocrinology & Metabolism.

[45]  Valerio Chiurchiù,et al.  Bioactive Lipids and Chronic Inflammation: Managing the Fire Within , 2018, Front. Immunol..

[46]  E. Tsilibary,et al.  A Review on Platelet Activating Factor Inhibitors: Could a New Class of Potent Metal-Based Anti-Inflammatory Drugs Induce Anticancer Properties? , 2017, Bioinorganic chemistry and applications.

[47]  V. Di Marzo,et al.  From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology. , 2016, Physiological reviews.

[48]  M. Lazanas,et al.  The Role of Platelet-Activating Factor in Chronic Inflammation, Immune Activation, and Comorbidities Associated with HIV Infection. , 2015, AIDS reviews.

[49]  Tracy E. Macaulay,et al.  Platelet Activating Factor , 2015 .

[50]  C. Barbas,et al.  Rapid and Reliable Identification of Phospholipids for Untargeted Metabolomics with LC-ESI-QTOF-MS/MS. , 2015, Journal of proteome research.

[51]  Q. Tong,et al.  The endocannabinoid system and its therapeutic implications in rheumatoid arthritis. , 2015, International immunopharmacology.

[52]  R. Pertwee.  Endocannabinoids and Their Pharmacological Actions. , 2015, Handbook of experimental pharmacology.

[53]  M. Cascio,et al.  Biosynthesis and Fate of Endocannabinoids. , 2015, Handbook of experimental pharmacology.

[54]  J. Ring,et al.  Rupatadine: efficacy and safety of a non-sedating antihistamine with PAF-antagonist effects , 2014, Allergo Journal International.

[55]  K. Mackie,et al.  Parsing the players: 2‐arachidonoylglycerol synthesis and degradation in the CNS , 2014, British journal of pharmacology.

[56]  N. Chatterjee,et al.  Endocannabinoids affect innate immunity of Muller glia during HIV-1 Tat cytotoxicity , 2014, Molecular and Cellular Neuroscience.

[57]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[58]  T. Nomikos,et al.  Platelet Activating Factor in Heart Failure: Potential Role in Disease Progression and Novel Target for Therapy , 2013, Current Heart Failure Reports.

[59]  Preeti Singh,et al.  Platelet-activating factor (PAF)-antagonists of natural origin. , 2013, Fitoterapia.

[60]  Lyubomir G. Nashev,et al.  Mineralocorticoid and glucocorticoid receptors differentially regulate NF-kappaB activity and pro-inflammatory cytokine production in murine BV-2 microglial cells , 2012, Journal of Neuroinflammation.

[61]  P. Castillo,et al.  Endocannabinoid Signaling and Synaptic Function , 2012, Neuron.

[62]  Verena D. Schmittmann,et al.  Qgraph: Network visualizations of relationships in psychometric data , 2012 .

[63]  D. Nomura,et al.  Endocannabinoid Hydrolysis Generates Brain Prostaglandins That Promote Neuroinflammation , 2011, Science.

[64]  Lawrence J. Marnett,et al.  Endocannabinoid Oxygenation by Cyclooxygenases, Lipoxygenases, and Cytochromes P450: Cross-Talk between the Eicosanoid and Endocannabinoid Signaling Pathways , 2011, Chemical reviews.

[65]  Agnes L. Bodor,et al.  The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors , 2010, Nature Neuroscience.

[66]  M. Nagarkatti,et al.  Endocannabinoids and immune regulation. , 2009, Pharmacological research.

[67]  Renato Malcher-Lopes,et al.  Glucocorticoid-regulated crosstalk between arachidonic acid and endocannabinoid biochemical pathways coordinates cognitive-, neuroimmune-, and energy homeostasis-related adaptations to stress. , 2009, Vitamins and hormones.

[68]  István Katona,et al.  Endocannabinoid signaling as a synaptic circuit breaker in neurological disease , 2008, Nature Medicine.

[69]  G. Cabral,et al.  Cannabinoids as therapeutic agents for ablating neuroinflammatory disease. , 2008, Endocrine, metabolic & immune disorders drug targets.

[70]  Takao Shimizu,et al.  Identification of a Novel Noninflammatory Biosynthetic Pathway of Platelet-activating Factor* , 2008, Journal of Biological Chemistry.

[71]  B. Cravatt,et al.  Anandamide Biosynthesis Catalyzed by the Phosphodiesterase GDE1 and Detection of Glycerophospho-N-acyl Ethanolamine Precursors in Mouse Brain* , 2008, Journal of Biological Chemistry.

[72]  R. Palmiter,et al.  Multiple pathways involved in the biosynthesis of anandamide , 2008, Neuropharmacology.

[73]  B. Cravatt,et al.  A Comprehensive Profile of Brain Enzymes that Hydrolyze the Endocannabinoid 2‐Arachidonoylglycerol , 2007, Chemistry & biology.

[74]  A. Weyrich,et al.  Intracellular PAF catabolism by PAF acetylhydrolase counteracts continual PAF synthesiss⃞ Published, JLR Papers in Press, August 10, 2007. , 2007, Journal of Lipid Research.

[75]  B. Jang,et al.  Dexamethasone suppresses interleukin-1β-induced human β-defensin 2 mRNA expression: involvement of p38 MAPK, JNK, MKP-1, and NF-κB transcriptional factor in A549 cells , 2007 .

[76]  Takao Shimizu,et al.  A Single Enzyme Catalyzes Both Platelet-activating Factor Production and Membrane Biogenesis of Inflammatory Cells , 2007, Journal of Biological Chemistry.

[77]  D. Hommes,et al.  Glucocorticoids cause rapid dissociation of a T‐cell‐receptor‐associated protein complex containing LCK and FYN , 2006, EMBO reports.

[78]  Ken Mackie,et al.  Cannabinoid receptors as therapeutic targets. , 2006, Annual review of pharmacology and toxicology.

[79]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[80]  A. A. Romanovsky,et al.  Platelet‐Activating Factor: A Previously Unrecognized Mediator of Fever , 2003, The Journal of physiology.

[81]  Y. Oba.  The use of corticosteroids in SARS. , 2003, The New England journal of medicine.

[82]  Carl Nathan,et al.  Points of control in inflammation , 2002, Nature.

[83]  C. Riccardi,et al.  Molecular mechanisms of immunomodulatory activity of glucocorticoids. , 2002, Pharmacological research.

[84]  G. Zimmerman,et al.  The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis , 2002, Critical care medicine.

[85]  G. Zimmerman,et al.  Oxidized LDL contains inflammatory PAF-like phospholipids. , 2001, Trends in cardiovascular medicine.

[86]  P. Peplow.  Regulation of platelet-activating factor (PAF) activity in human diseases by phospholipase A2 inhibitors, PAF acetylhydrolases, PAF receptor antagonists and free radical scavengers. , 1999, Prostaglandins, leukotrienes, and essential fatty acids.

[87]  C. Leslie.  Properties and Regulation of Cytosolic Phospholipase A2 * , 1997, The Journal of Biological Chemistry.

[88]  A. Yamashita,et al.  2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. , 1995, Biochemical and biophysical research communications.

[89]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[90]  J. Vane,et al.  Induction of cyclo‐oxygenase‐2 by cytokines in human pulmonary epithelial cells: regulation by dexamethasone , 1994, British journal of pharmacology.

[91]  S. Munro,et al.  Molecular characterization of a peripheral receptor for cannabinoids , 1993, Nature.

[92]  D. Gibson,et al.  Isolation and structure of a brain constituent that binds to the cannabinoid receptor. , 1992, Science.

[93]  N. Inagaki,et al.  Studies on the anti-allergic mechanism of glucocorticoids in mice. , 1992, Journal of pharmacobio-dynamics.

[94]  F. Snyder,et al.  A coenzyme A-independent transacylase is linked to the formation of platelet-activating factor (PAF) by generating the lyso-PAF intermediate in the remodeling pathway. , 1991, The Journal of biological chemistry.

[95]  M. Herkenham,et al.  Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[96]  F. Snyder.  Platelet-activating factor and related acetylated lipids as potent biologically active cellular mediators. , 1990, The American journal of physiology.

[97]  H. Yasuda,et al.  Mechanism of increased angiotensin-converting enzyme activity stimulated by platelet-activating factor. , 1990, Biochimica et biophysica acta.

[98]  F. Snyder.  Platelet-Activating Factor and Related Lipid Mediators , 1987, Springer US.

[99]  D. Hanahan,et al.  Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). , 1979, The Journal of biological chemistry.

[100]  W. J. Dyer,et al.  A rapid method of total lipid extraction and purification. , 1959, Canadian journal of biochemistry and physiology.